Optimized a complex CRISPR-Cas9 protocol, enhancing gene editing efficiency by 40% in primary human T-cells at Gilead Sciences. This critical advancement accelerated a novel CAR-T cell therapy candidate through preclinical stages to IND-enabling studies within a rigorous 12-month development timeline. The success significantly de-risked early development and demonstrated a robust ability to troubleshoot and refine cutting-edge molecular techniques under pressure.
During my tenure, I developed and validated a novel multiplex qPCR panel for early viral load detection, reducing assay turnaround time by 30% and enabling faster therapeutic adjustments in a large-scale clinical trial. I also streamlined Western Blot protocols for membrane protein analysis, resulting in a 25% improvement in signal-to-noise ratio and significant time savings in sample processing for drug target validation. Furthermore, I led high-throughput ELISA screens for antibody-drug conjugate binding affinity, processing over 500 unique samples weekly and generating critical data that accelerated lead candidate selection by two months.
Veridian Therapeutics' recent breakthroughs in targeted gene delivery systems, particularly your work on non-viral vectors, deeply resonate with my expertise in CRISPR-based genome engineering and cell culture. My strength in optimizing complex biological systems and my proficiency in R and Python for data analysis align perfectly with the innovative, data-driven approach I understand your team employs for advancing next-generation therapies. I am confident my contributions can significantly support your pipeline.
My background in advancing therapeutic candidates from early discovery through preclinical validation, combined with my specific technical proficiencies, positions me as a strong fit for your Scientist role. I am eager to contribute to Veridian Therapeutics' mission of developing life-changing treatments. Thank you for considering my application; I look forward to the opportunity to discuss my qualifications further.
Best regards,
Brandon Jackson